Log In
Print this Print this

altiratinib (DCC-2701)

  Manage Alerts
Collapse Summary General Information
Company Deciphera Pharmaceuticals LLC
DescriptionOral small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1; VEGFR-2), c-Met receptor tyrosine kinase and tyrosine kinase receptor 2 (Tie2)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) ; c-Met receptor tyrosine kinase
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; c-Met receptor tyrosine kinase inhibitor; Tyrosine kinase receptor 2 (Tie2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors; Treat solid tumors and highly invasive metastatic cancers
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today